Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

ArjoHuntleigh AB, CMD

By Inderes9/24/2026, 7:00 AM
Arjo

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Unknown 1
00:03 - 01:20

People are made to move. It is at the heart of being human. From the moment we're born. Until we inevitably slow down. Movement is freedom. But what if that changes? What if every movement becomes an effort? What have you come to? A complete standstill in care. The impact of immobility is felt by patients and caregivers, both physically and mentally. And in care facilities, costs and inefficiencies can spiral. Movement goes beyond putting one foot in front of the other. It promotes healing and helps provide residents with the independence and dignity they deserve. It protects caregivers and empowers effective facilities. That's why empowering movement is at the heart of everything we do, and why our solutions are designed to keep everyone moving. For 70 years, we've responded to the needs of healthcare professionals for the benefit of those who depend on them. Through the right equipment, environment and skills, we offer caregivers and care providers the ability and confidence to always deliver quality care today and tomorrow. This is our focus, our cause. Arjo, empowering movement.

Maria Nilsson
01:36 - 04:09

Good morning, everyone, and welcome to Arjo. Arjo Capital Markets Day. It's great to see so many of you here today, both here at Epicentre in Stockholm and online. Thank you for taking the time to join us. My name is Maria Nilsson, and I lead communications at Arjo; I will be moderating our session here today. We have been looking forward to sharing an update on where we stand today. Presenting our new strategy, the plan to deliver it, and the priorities moving forward. We also want to go into how we will create value for patients, caregivers, customers and shareholders over the coming years. And we want to give you a clear understanding of the priorities, the strategic choices we've made so far, and why we believe that Arjo has significantly greater potential than what we've demonstrated in recent years. The plan we will present today has been developed through a broad and collaborative process involving leaders from across the company. It is a plan we are confident in, not only because of the opportunities we see, but because it has been shaped together by the people who know our customers, our markets, and our business best. So we have an interesting morning ahead of us. You will first hear from our CEO, Andréas Elgaard, who will present his view on where Arjo stands today. The new strategy we have put in place and the priorities will guide us forward. We will then take a closer look at two of the markets where we see significant potential for further growth and value creation. This session will be led by two highly experienced commercial leaders. First, Jessica Shatzer from the US will share her perspective on our largest market and how we see that we can further strengthen our position there. Then we'll hear from Canada and Jim Findlater, who will share insights into a very interesting market for Arjo and how we can continue to further grow profitably in this market. Following the presentations, we will conclude with a Q&A session where you have the opportunity to ask questions. And with that, I am handing over to our CEO, Andréas Elgaard.

Andréas Elgaard
04:21 - 39:06

It is a pleasure to be here. My name is Andréas Elgaard. I'm the. I have had the privilege of being the president and CEO for almost nine months now, so I am as excited as you are to be able to talk about what we have been doing during these months. It has been, for me personally, a true privilege to discover Arjo, the people, and all the good things that we do. And I think there is more good to be done. And that's what we will start to share today and in the coming periods. So let's see if we get the slides up. Yeah. So we just sent out a press release. For those of you who have started to see that, I will come back to that a little bit later. But we make a commitment today that within the next 30 to 36 months, we will deliver a clear profitability improvement of 350 MSEK. And the majority of that, the vast majority, will happen within the next 24 months. But first, I would like to begin by talking about who we are before we discuss the reality for healthcare and what Arjo needs to do in order to address that in a better way going forward. So I will begin with our starting point. And you can say that our core and our purpose are very well aligned. We really help patients when they need it the most, and we will come into that. Our starting point is really to be experts across different care settings and help people with their mobility in and out of bed, coming from a chair into the bathroom, taking care of personal needs, and to do that with respect and dignity. So that's what we do. And we are a company that has grown both organically and inorganically. And we were founded. The name comes from Arne Johansson back in 1957 when the company was first started. And then it has, of course, grown and added more capabilities to the company. Last year, we had 11 billion SEK in turnover. We are almost 7,000 coworkers around the world. We have sales in more than 100 markets, and we are truly a diverse company. I must say that both from a market perspective and an employee perspective, and of course, from a customer perspective, we produce, assemble, manufacture, and offer products across five different facilities, while also working with several partners that help us fulfill our offer. So, and our. I mentioned that we really have diverse markets and a diverse customer base before. And that is something that is truly good. We have diverse segments. We have customers that are diverse, and we have the different markets. This means that we have become quite a stable company when it comes to generating our revenue. You can see that the segments we are in—patient handling, which is very closely connected to mobility, is the biggest area, and medical beds and pressure injury prevention are also very important. And all these help patients to stay mobile and prevent the dangers of being static in the care setting. You can see that when we have our different quarterly reports or discussions with different members of the financial markets, there are a lot of questions about North America. So today we will have Jim and Jessica help us to get a deeper look into that. North America accounts for almost 40% of our sales. We have activities as far away as Australia. We are in South America. We are present there. I think last year, our 10th largest market was India. It is amazing to see the business that has been built up there. So we are truly a diverse company, I would say. And it is a mix of capital goods, recurring revenue through services, and rental. And of course, we also have disposables as part of this, which helps to create stickiness in how we do our business. We believe that we have a really solid foundation in our core to base our growth on when we move forward. So everything from the customer base to our teams, our know-how, and our competence, to the underlying business, gives us the foundation to be able to move into the future and also provides us with a solid base to build upon. Circularity is something that is really important. More and more markets, tenders, and public expectations regarding circularity have become a hygiene requirement. And almost 45% of our business has really circular qualities, both in the rental business and in our service business. And we try to build this into our capital goods business as well. And I think this is probably what is most important and most striking. And when I was new to Arjo, this is what I felt the strongest. It is that we have a true purpose. We do good for people when they need it the most, when they need their dignity and integrity kept. We are there to help them. That is something that is truly unique, as there are many companies that have a purpose, but when you really feel it across the organization, it becomes something to build upon, and it is something I have felt when I have traveled and met all of our people, as this is a value they consistently return to. And when a rental technician is late with a delivery, they know because they meet the patient, they see the caregivers that are waiting. So the purpose is so close to everything we do, and that is what is being brought back into everybody that works more centrally in the group. So in many aspects, Arjo is really, really great. Great people, great leaders, great solutions. But as you know, sometimes that is not enough, and we are not good enough. We know that in recent years, we have not lived up to the expectations that we put on ourselves. We have not lived up to the expectations that the market put on us. I will provide a brief retrospective before we look forward to the actions we need to take. So as I said, recent years' performance has left us a bit unsatisfied. Both. I think this is something that all shareholders share, and it is definitely something that everybody within Arjo is also sharing. And you can see that when Arjo stood alone as a company on the stock exchange for the first time in 2018 after the spin-off from Getinge, there was a couple of years with, I would say, entrepreneurial spirit, pioneering, being free, building up everything that you need to have as a freestanding organization. Those were also good years. I would say the market was predictable. We were moving forward. And then we entered the Covid-19 period. And I would say for Arjo, that was really good in some aspects. But when you look deeper, there were some problems already back then that we may not have seen because we were busy satisfying the tailwinds that we had. And we did not really see that parts of the business were actually facing headwinds, and after Covid, I would say that reality became super clear because when some of the more easy sales that we got disappeared. The reality came back. And you can see that our performance since then has not been satisfactory. What is good to say is that we have managed to keep the top line growing throughout this period. The CAGR has been there, and I think that has also helped us to keep up profitability. But still, this is not what we expect from ourselves. We need to do much more and much better. And part of this is also that the strategy that was launched in this period did not really work. So the outcome-based ambitions that we had never really materialized. And I would say since 2022, that became a really harsh reality for many. I think that Arjo has been a little bit in a waiting mode in some aspects. In other aspects, I would say all the markets and everybody taking care of customers continued to focus on the underlying business, but we got a little bit derailed and lost some of our focus during those years. And of course, when you look at the financial targets, we have had a hard time living up to those. We have met the growth targets, but we have had a hard time to generate true cash flow. We have struggled to reach our desired adjusted EBITDA margin. And I think we have continued to have dividends, but it is time now. I think when these goals were set, they were set to last until 2025. And right now, we are in the process of determining which goals we need for the future because we require new financial targets. That reflects the new strategy and the new reality that we live in. So we will come back to that in Q1. We wanted today's focus to be on strategy and not on the financial targets. And what you can expect out of the strategy is really what the message is today. So before I come into the strategy, I just want to pause a little bit because healthcare is not standing still. It is evolving. And I would say that is also why Arjo needs to evolve. We cannot provide yesterday's solutions to tomorrow's problems. So we really need to speed up the change in our company because the reality out there is really clear. So there's a number of megatrends. You all know this when you cover other similar companies to Arjo, other medtech, but also other industries, because many of these things are shared. So, if you look at the aging population, it just means that we need more. We need care during a longer period of our lives. It puts a lot of pressure not only on the pension system, but on the health care system, because people will live longer. That is something fantastic, but it also puts a lot of pressure on the healthcare system at the same time. Young people do not show the same appetite to work in health care, which means that the sector is squeezed and they need solutions that help them to be more efficient. They need solutions that help to protect the health and well-being of the caregivers, but they also need solutions that help to provide the care that they need to deliver. So this is something that, of course, has implications for Arjo that are positive, as the solutions that we provide and the content that we have will be needed even more in the future. Of course, with increasing global welfare, more and more people are coming out of poverty and into the middle class. That also comes with expectations. They expect more. They are not satisfied, perhaps, with the type of care that they saw their parents receive. They say they want something more. They are more aware of their rights. This is also putting increased pressure on our health care facilities and institutions, and the public or private funding of those. Then, of course, digitalization, AI, and the democratization of information. We single out both because one is driven by being able to leverage data, automate, and drive efficiency. The other one is really about what people expect. People expect to have access to information. They expect to be able to keep up with what's going on with their loved ones, and also people that need care. They want to know what is happening. We can see more and more that they expect more, they expect information, they expect to be updated, and they expect to be able to follow. This is increasingly putting pressure on systems that historically are quite late to change and that are big. And that requires a great deal of trust before they attempt to change. And those of you who are from Sweden in the room today, you know how the regions across Sweden are struggling when they need to update their IT systems, when they need to drive their efficiency, because they are not always the best at procurement. They are not always experienced in driving these types of things. So, being a partner to healthcare providers is also a big part of what we need to be better at. The good news is that we are in markets and in care settings that are growing because of these trends. The need for care is just growing. And our health care settings are struggling to keep up both with funding and the ability to provide that care. And as a result, you see that acute care is still growing, but the number of nights that you are in acute care is going down. It is almost measured in hours. And of course, that puts more pressure on Long-Term Care to keep up. And we know that the number of years that you are in a long-term care facility today has also gone down dramatically. And more and more care happens in the home. And that care that happens both, I would say, in long-term care has become more advanced, more clinically advanced. And also at home, it becomes more and more clinically advanced. So the needs are being pushed down in order to be able to cope with the bigger reality of what patients require. But of course, we operate in this market, the market is growing, the need is there, and we can make a difference. That is something really positive. We wanted to share that, of course, Acute Care is the biggest market. Long-Term Care is also really interesting, as is the adjacent Home Care sector. That is where the growth is the biggest. And you can see that our position today in some of our categories is quite strong, including patient handling, VTE prevention, pressure injury prevention, and hygiene. We are in the top three positions, and that is something really strong. And then medical beds. We are in a top ten position and the beds are, if you look at it from a gross profit point of view, maybe a little bit lower, but it is also something that creates a stickiness in the relationship, and it is something that gives you a need to come back because we have the mattresses that go on the beds and we help the patients to get in and out of beds. It is a very significant part. It is the center of each care setting. So it provides us both with the know-how and the market position that is required. So that's a little bit of what's ongoing in the market and about our position. We are not happy with our performance over the last year. So now we need to focus and we need to build on our strengths. We need to remove some of the clutter that may have caused us to lose focus in recent years, and truly concentrate on our core business to build a platform that is more scalable for growth and expansion into new markets and care settings. And if we want to accelerate M&A in the future, we need to do that also from a scalable base. So with that, I will move into our strategy. And for Arjo, it's all about 'Make the Move' and doing that together, and we emphasize that 'Together' aspect. Part of it is because I am new in this industry; I come from another type of industry. My profile is that I am a people person. I am a leader. I am a transformational type of leader. It is all about getting people to develop and grow and pull in the same direction. Then you get Arjo to also develop and grow. And if we start to pull in the same direction, that's where the focus comes in. And that is where you can expect positive output. So this strategy has been developed by gathering people from all across the organization. Arjo, it's not a top-down initiative. It is really a well-founded strategy with all our professionals and with all the diversity and all the experience that we have. But maybe that has been kept in pockets, and that has been a little bit unknown to parts of our own organization. And I would like to begin with this. In the strategy work, we decided to put our foot down and try to describe how we want our customers to perceive us. So we formulated what we call the wish position, and that is to be the partner healthcare providers look to when shaping better care, trusted for understanding their needs, being easy to work with, and delivering value through purposeful solutions. This is easy to put down on paper. It is already what we are known for by some of our customers. But it is really hard to maintain that perception consistently and to live up to the promise that we make to ourselves, because that is truly how we want to be perceived. And it's who we are striving to also become when we are not meeting up to it. And this is something that is constantly evolving. This is not a static place that you can reach. And then you are there. This is something that is always moving ahead of us, as the expectations, the needs, and what is purposeful will always change. Now I will go into and talk a little bit more. So what is it that we are going to do? What is behind the plan that will put Arjo back on track? So we have clustered this into three buckets. The first one we call win, where we have the right to play. This is all about us having confidence. We have the competence. We have the solutions. We have the position in the market. We have the trust from our customers. So we know that we have a right to play here. We know that we have the offer. We know that we have the know-how. This is super important because it means that we can act with competence. What we have not done is that we have not always used that. So we sit with this fantastic situation, but we don't execute it consistently across Arjo. So that is what this is all about. It's really about owning and expanding leadership in Long-Term Care. Strengthen our position and scale up in Acute Care, and then selectively expand into new care settings. This could be Home Care. It could also be transitions between different care settings. The word selectively is important here, because in the past we have made promises about businesses that are small today but will be big in the future. Here we want to prove results. We want to be sure before we make commitments that we expand into new types of care settings where we are more pioneering. We will delve into this. I will spend the majority of the time explaining a little bit more about this. So you get a better feeling for that. Then I will also come into the area that we call Simplify to Amplify and the part that is working better together. So if we start with the first one, these three priorities are very important. It is all about our core strengths. And you can say that if you talk about Home Care, we already have parts of our business in most of our markets coming from Home Care. So we know much more. We just need to spread that across the company. So let me elaborate on this. So if you look at the Long-Term Care situation, we have a proven leadership. We have market-leading positions in many markets. We have the know-how. We have the offer, we have the solution, and we have the relevance. And then you can look at a neighboring country and see that the situation is completely different, but the care need is the same. People need the same thing. The trends are the same. The reality of the healthcare system is the same. It's just that there are different ways and routes to market. But when you have the know-how and the confidence, it is easier to then explore that. So this is all about us seeing that we have a lot of penetration that we can do and build on our internal know-how. And it is so much easier to unlock that when you have a colleague, or two, or three, or 100 that have done this, versus if you need to do a project where somebody comes in from the outside and tells you how to win. Here, we already know how to win. I would like to point out that in Canada today, 65% of our sales are in Long-Term Care. And we all know that the US, being our biggest market, means there is so much we can do. We already cover the country. There is so much more we can do from that base. And that is the plan going forward. So you can see the potential here. Acute Care is our most important sector. We see that Long-Term Care perhaps has the biggest growth, profitability, and opportunity. But Acute Care is most important in terms of scale for us. And we also have most of our know-how and most of our relevance here. Again, our strong position gives us the confidence that we have the offer and the competence. We have the position. We have the trust. We have the examples. We have such good relationships with our customers that they are willing to help and share that with others who are willing to try and test Arjo in Acute Care. And we see that there is substantial room to scale this up. And in our plans, we think that we should not promise too much, but we see that there is opportunity. Really good opportunities for us here across all our markets to do better. Maybe in the US it's hard to keep on penetrating, but there we have the opportunity of Long-Term Care. So, looking at the internal situation, you can imagine what the next few years will look like. It will require investments. But I think that will be really worthwhile because they will be less risky than some of the investments that we have done in the past. And then the third and last one, and this is just to point out on the bottom here, you can see that in Great Britain today, 12% of our sales is actually in Home Care. And we have not really highlighted that. And we mentioned a couple of other markets. So if we can start to move the needle here, if we can start to become a little bit more relevant in some of these care settings, because today we enter Home Care with solutions that have been developed for professional care settings. Since the care need is becoming more and more professionalized across care settings. That is a good trend, but we probably need to be more relevant specifically for the home care setting. We have a foothold also here. We have competence, but we are not as confident. That's why we say that we need to be selective. So let's pick some. If we do something in the US or Canada, let's pick a part of the country. If we do something in Europe, let's pick a market where we think this is good for us to move forward with. And when we have the proof, we can be more bold in our commitments to you and to all our shareholders. So, yeah. The simplify to amplify part is all about winning, where we have the right to play, what we do, how we leverage our market position, and our commercial know-how and value proposition. This is more about us getting our act together. Over the years, we have grown organically in our offer and in our value proposition. So we have a need to prune our portfolio. We have a need to make sure that we are efficient across our value chain. Today, we have not performed that job effectively. This is something that I am really passionate about. I have seen how much value can be unlocked when you do that, and it is something that we have also seen when we have made the strategy that there is appetite for this in Arjo. So that will be very, very important. And commercial excellence, since we are such a diverse company, since we have so much empowerment, we have so many examples that are great. And you can, as you know, figure out that we also have examples that are not as great. So we have a lot to do here to be more diligent in our commercial excellence and execution. I will not go into this too much on how we become a digital and AI-enabled partner, but for us, this is mainly about driving internal efficiency. Most of our products are not connected. We know that the need to be connected is growing. We have a couple of pockets of excellence and visited one of those just last week, together with our board of directors in France, where we keep track of all equipment in a Long-Term Care facility, not just the Arjo equipment, but also all of our competitors' equipment. We have the know-how, but we have been a little bit careful in scaling, as we have not built the organization to scale it. So that is something that we need to do in the future. So, I will not go into that today. I will just show this to you. So this actually looks like it is just illustrative, but there is actually real data behind it. So we have a super long tail. And those of you that have worked more operationally, you know, when it looks like this in an organization, you have a lot of capacity. You carry a lot in inventory. You need to have all your documentation in order for everything. There have been many years of launching new solutions and updated versions without removing old ones, and that just adds to the complexity, and complexity in a value chain is cost. And that is something that we need to address. But we cannot do that just by optimizing from a procurement point of view or from a manufacturing point of view. We need to make sure that we have our markets and our customers with us in that journey. So this is really an end-to-end initiative that we need to undertake. But there is significant potential to be unlocked here in making Arjo more straightforward, more simple, and also help us to release the space to come with new innovation. I just showed this is also coming from real data. This just shows how our pricing is varying depending on where we are across different products, our margins in different markets, and different settings. There is always a normal variation, but you can see we have quite big variations here. So we believe that there is a lot we can do in terms and conditions, pricing, service charges, and so on that can help us to move the needle here. And then the last cluster of strategic priorities is working better together. That is about how we get all the know-how and all the diversity that we have at Arjo to start pulling in the same direction. Because when you have so much diversity, but you don't make use of it, it becomes complexity, it becomes noise, it becomes clutter. So we need to pull together. That is also why we developed the strategy together. And I think that we have engaged around 80 of the most senior leaders around. Our strategy that we developed, half of them were part of creating it. The other half is now onboarded and we are rolling it out step by step across Arjo. So if we get the people to develop and grow, then Arjo will develop and grow. That is really one of my mantras. One part of that is to work on our operating model. So I will come back to that. But this is probably most important to build a performance-driven culture where our purpose is always at the center. And that purpose is really to help patients when they need it the most. And that is for real. But we need to realize that is not enough. We also need to have a performance culture built into that. So making profit and being successful helps you to invest in yourself, in your people, and in your competence. It helps you to invest in R&D. So we need to make sure that we have that culture end-to-end across Arjo when we move forward. And that starts with investing in our leaders and empowering our people. That is highly important. And to make sure that we are striving towards the same goals. That is the reason for our strategy. It is not about what you put on the slides. It is about making sure that you have the motivation in your organization to pull in the same direction, and the only thing that counts is what you execute. What we have up here, it is only what we execute that will count. And then you need to make sure that everybody understands that it's not just Andréas who will do the execution. We have created this strategy together, and it is not a case of somebody else executing it. No, it is us that need to execute. I would say working better together is very closely connected to how we deliver our care, how we help caregivers, and how we then become more efficient in that. But it also relates to our purpose. And that purpose more and more becomes also about when we do things that are good. It also needs to be sustainable. Much of our business already today has circular qualities, but we need to make sure that is something that we build into how we design new products, how we design our packaging, and how we design our value chain. With my own background, what I have experienced is that the more you work with sustainability, the more you work with efficiency, because it is all about removing clutter, removing noise, doing things smarter, and doing things straighter. But I will talk a little bit about our operating model now. We communicated just before summer that we are organizing ourselves in five regions. These are not five segments. These are five regions in how we cover our customers. So, for the US and Canada, for obvious reasons, we don't group North America together. It is also two very different healthcare systems. They are funded very differently. We have different cultures. And then we know we also have this friction going on now that I think is not healthy for anyone. But the US is our biggest market, and Canada is one of our most profitable markets. So it is natural that the US and Canada deserve a seat at the table. South and West Europe. So that is France and the UK, our biggest markets, but also Italy, Spain, and Belgium, where we keep that part of Europe, the southwest cluster, together. North and central Europe really comprises the Nordic countries, the Netherlands, the Dutch region, and parts of Poland and the Czech Republic. And then we have the rest. 88% of the population, but not 88% of our sales. But it is still a major part. So that is where we have Africa. It is where we have Latin America. It is where we have our different activities. We have activities across Asia, as well as Australia, within that cluster. Australia is our biggest market, with India being the second. And the reason why we want to do this is because we want to raise performance. I mean, this sounds simple. I almost feel bad saying it, but we need to increase our proximity to our customers. We need to make sure that the voice of the customer is present in every decision. The voice of the customer is present in every decision that we make as an organization, in how we prioritize our investments, in how we prioritize our portfolios of development, and in how we assess if a product will be commercially viable or not. We need to make sure that we do that in a much more commercially relevant way than what we have done before, and that we do that early in the process and not towards the end of a process; that is really how you speed up time to market. How you increase quality. And most importantly, perhaps, is how you can then drive profitability by being relevant to your customers; to support that, we also put in a new function that we call Group Sales. Group sales is not leading the regions. The regions lead themselves and they report to me. But group sales has the job to help with commercial best practice and commercial excellence, and to coach the regions and help them to collaborate. Arjo does not have a strong collaboration culture today, so that is something that we need to drive and enable. And group sales has that role in that dimension. Group Portfolio is a new function that we have created, where we bring R&D, group marketing, and our portfolio leaders together into one group, and they will have the responsibility to, with our own resources and with our external partners, drive the development of our portfolio, but also drive the portfolio pruning that we need to make in order to become more efficient. Group operations is, of course, our procurement, our assembly, and our manufacturing, but this will now also include the responsibility for our OEM partners. That has not been the case in the past. We are taking end-to-end responsibility for operations, just as we are doing for portfolio. In the past, we have let some of our countries do their own thing without support from group functions. And that has left the markets very vulnerable. And that is something that we need to help them to straighten out. And then, of course, we have all the other good stuff that you need to have in a company: finance, quality, HR, legal, communication, and whatnot. Of course, but most important here is that we are also going to be really focused on execution. So the strategy that we present will be executed. That is it. That is how I function. I would not make a promise if I did not know that we were going to execute it. So we're going to execute this and deliver what we have said. And by that, I think it is time for you to have the opportunity to stop listening to me. And instead, I would like to welcome Jessica up on stage.

Unknown 2
39:12 - 39:12

Thank you.

Jessica Shatzer
39:21 - 51:47

Good morning, everyone. I'm so happy to be here with you today. My name is Jessica Shatzer. I am the Vice President of Marketing in the US, and I have been working in US healthcare for the past 16 years. health care for the past 16 years, 13 of those at Arjo, and the last five leading the U.S. marketing organization. And I'm thrilled to be here today to talk a little bit about the US market overall. I will also discuss the US Arjo organization. And then we'll go into a little bit more detail on a couple of the strategies that Andréas has already laid out that are most relevant for the US. So let's dive in. Starting with market characteristics, many of the high-level market characteristics are similar to what Andréas Elgaard described in some of the trends. So I won't go into detail on those, but I did want to highlight a couple that are most relevant for the US. The first one I need to call out is the bariatric trends in the US because of the prevalence of GLP-1, and we have had a lot of questions on whether we see a decline there. What we have seen is a slowing in the trends around obesity, but we have not seen massive reductions like some people may have anticipated. We have actually reached 42% of U.S. adults who are clinically obese. adults as clinically obese. So there is still a massive need for the bariatric solutions that we offer. Next. If we look at financial and operational aspects, I feel like I have been here for a long time. So I have seen this history of financial issues with customers, including what happened pre-COVID, during COVID, and post-COVID. Now, in an exceptional post-COVID world, I would say that there are three different tiers of customers. And actually, our credit rating agencies have called it a trifurcation within customers. Some are doing really exceptionally well, some are doing quite poorly, and a good chunk of them are right in the middle. So the average operating margin today for a US hospital is about 1.3%, which has risen over the last number of years. Interestingly, though, two areas where they are investing: one is around capitalization. We have seen more capital investment over the last year and a half than we have in many years. Meaning instead of renting products, they may want to make a purchase of medical beds, surfaces, or other equipment in their facilities, among other areas. New healthcare construction. That could be a new facility. That could be a renovation of an existing facility or a new tower. And we've seen that increase 11.2% year-over-year in the market as a whole. Next, the increasing focus on preventable events. This has been a focus for a long time in the US. It has mainly been a focus in Acute Care. What we are seeing now from the US government is a lot of those regulations pushing down to the Long-Term Care world. So think of things like patient falls or pressure injuries, where there will be a financial impact for not meeting certain standards. Right there with customer dynamics, healthcare mergers and acquisitions are accelerating. A lot of these things that I am mentioning, the new construction and healthcare M&A, are all efforts for them to increase their profitability. They are also looking to diversify. Another area where they are focused is moving some patient volumes into Ambulatory Surgery Centres. So more and more surgeries are moving from traditional inpatient to an outpatient situation where patients are discharged on the same day. And then lastly, something that we will talk about today in more detail is sustainability. Sustainability has been a strategic initiative for a smaller subset of hospitals and health systems within the last few years. I would say it is becoming more mainstream and more important for them, and we have been able to position ourselves as a good partner within that space. So I hope the key takeaway here is that the underlying demand for our products and solutions at Arjo is strong based on the US trends. So at a high level, Andréas already shared where we get the bulk of our revenue and sales from, and that is in Acute Care. We also have about 10%. That comes from Long-Term Care, a smaller 3% from Home Care, and an even smaller 2%, which includes sectors such as prisons or schools. In the middle, you can see the categories that drive most of our revenue. We have market-leading positions in categories such as patient handling, rental, and VTE prevention, and those really drive the bulk of our revenue. We also have a very strong service offering. That is very important to what we do as well, including how we deploy. We are deployed across the United States. We have around 850 employees and 63 service centers. That is really important for the rental and service component of what we do. And we deploy through a direct sales and service model, which is very important because that customer intimacy that Andréas Elgaard talked about is highly related to this and the relationships that we can drive. One way that we truly differentiate is through our clinical expertise and the clinical support that we provide. That is something that we highly value and our customers highly value. And then we are home to the flagship ReNu reprocessing facility. So Arjo acquired ReNu Medical back in 2018. That facility is in the United States, and that has remained a large component of our strategy. So as you can see, we have a very strong position in the US, and that is really built upon our acute care leadership position. We have had seven consecutive quarters of profitable growth. You can see that we have a greater than 7% CAGR in our capital categories. That actually jumps up to low double digits when we are talking about patient handling on its own. And we have a 7% CAGR in what we call core rental. So many of you who have been following us for many years know that there is a product within critical care that has been highly volatile. It is one specific product that drives or has historically driven a large amount of revenue. Because it's so volatile, we tend to take that out and call that core revenue. So you can see that the base of the business and that underlying business is quite strong. On the right are some of the key drivers for us. We have a large, what we call, installed base. We have been in the market for many years. We've been in the US since 1979. There are many products out there that are Arjo products; because of those deep relationships, the quality that we offer, and the new products we have introduced, customers choose Arjo again when they go to replace those products. That is very important. Next, we have strong traction in product sales. On the previous slide, I mentioned the trends within new construction. We have been able to leverage that not only from a product portfolio standpoint, but through relationships with architects and new construction planners, where it is a full Arjo solution, not just a product solution. And then lastly, we are expanding partnerships with key hospital networks, what we call integrated delivery networks. So, with some of these big consolidations that are happening across the US, we have the relationships at the highest levels with some of these facilities and great partnerships that really drive not only one product category, but we try to drive the full breadth of Arjo solutions within that. I'll just give a quick example here. We had a customer recently. The opportunity actually started from a replacement opportunity. They had some equipment that needed to be replaced. We were able to go in and have a more consultative conversation, realizing there were some problems with pressure injuries, falls, and mobility. We were able to elevate that conversation. And then it went even further away from patient handling and into DVT prevention or VTE prevention and rental. So again, just a small example of how we were able to drive the full breadth of Arjo solutions. So obviously, things have gone well for us from an Acute Care standpoint. But there is a lot to lean on from an opportunity side. So let's go into a couple of those, being Long-Term Care and reprocessing. I don't think I need to sell you on the value of Long-Term Care. You saw how much revenue Canada generates. A lot of our other markets are very strong in Long-Term Care as well. We have the product portfolio here. We have the solutions to really deliver, but we haven't fully tapped into this market. There are 16,000 nursing homes and skilled nursing facilities in the U.S. today. We access only about 3,000 of them with our existing footprint and sales force. Within those 3,000, we are mainly only selling patient handling equipment. So obviously, there is a huge opportunity here to work with our existing customers and partners and pull through the rest of the Arjo portfolio. We also have an opportunity to sharpen our value proposition. Value proposition. We don't want to be seen as just a product provider for our partners. We want to be seen as a full solution provider who is able to be consultative. We can help with patient outcomes and resident outcomes, and in doing that, we really need to lean on that clinical expertise that I mentioned earlier. And lastly, in order to fully penetrate and address this market, there does need to be investment in the direct sales force and also distribution partnerships that already have access to the areas that we'd like to target. So next, advancing sustainability. This is that reprocessing that I talked about. And for anyone who is not familiar, most of the products that are sold into the US market are disposable, single-use products. So they are used with one patient and then thrown away. You can imagine the waste and cost that drives into the healthcare landscape. So customers have a desire to reprocess or reuse those items again; the main method that we as reprocessors do that through is with ethylene oxide, which is a toxic gas. We call it EtO. So Arjo ReNu offers a solution that is cleaner and greener and does not use ethylene oxide whatsoever. It uses a hot water method. I say that just to set the foundation for why this is so important. There are massive amounts of equipment and devices going into landfills that we will now be able to divert and use again for customers, not only helping their sustainability conversation, but also helping drive cost savings within the reprocessing world. It is much more cost-effective to reprocess a single-use device than it is to manufacture a new one. So there is a good amount of profitability in this category for us. So what do we need to do here? The first thing is to expand our reach. We work with some of the nation's top and foremost thought leaders from a health system standpoint, and we need to leverage some of those relationships to bring on new Arjo customers. We are also working on deploying new business models. Today, we only reprocess non-invasive medical devices, and we are working on a program that allows us to capture invasive devices and reprocess those through partnerships. And then lastly, broadening our capabilities. One thing that's really important with reprocessing is that you're continuing to look for new types of products to reprocess. So that is something that is consistently part of our strategy to try to drive new business within existing customers, as well as new customers. So what I hope that you've taken away from this short presentation is that the US remains an attractive market. We are going to continue penetrating the Acute Care market and doing everything we can to grow that. We are going to be leaning on some of our counterparts, like Canada, to help us really dive deeper into Long-Term Care and get good penetration there, as well as continue on the path with reprocessing. And we will do everything we can to execute on the strategy that Andréas Elgaard has laid out for us today. So with that, I will hand it over to Jim Findlater, our Vice President of Sales and Marketing for Canada.

Jim Findlater
52:00 - 64:02

Thank you, Jessica. Thank you, Andréas. It is really great to be with you all today. My name is Jim Findlater. I lead our sales and marketing team in Canada. I have been in the health care industry for about 17 years, 15 of which I have had the privilege to work for Arjo and support our customers across the country. I have had the ability to do that in many different capacities within Arjo, leading sales and marketing teams. I have had a unique ability to interact with stakeholders externally, from frontline staff to C-suite, which provides a lot of really interesting insights that I can share with you today. So I will start with what is going on in Canada. Andréas talked about this as a trend at the beginning of his presentation. But in Canada, the average age of the patient and the resident is increasing on an annual basis. They are staying at home longer and then entering institutional care with much higher acuity needs and less mobility. And then they're coming into institutions that are overburdened right now and have significantly fewer resources than they've had historically. So essentially, what we are saying is our customers are being asked to do a lot more with a lot less, and we are uniquely positioned to be able to support them there. The Canadian healthcare system in general looks something like this. Just under $400 billion was spent on health care in Canada, which is about 12.7% of the GDP. What is unique about our situation is that you might look at it and see one country, but in fact, what we have is 13 separate markets across the country that operate very differently. You take that 71% of public funding, and how it's disseminated in each market, in each province, and each territory is different. So, we are working with different health authorities, regional health authorities, provincial health authorities, and municipalities. But what I will say is that there do seem to be shared priorities across the chain. So we are looking at expanding access to primary care, supporting health care workers, reducing the backlog, and supporting access to home care and safe Long-Term Care. What our customers in Canada are currently craving, both in long-term care homes and acute care facilities, is the creation of efficiencies once again. We are uniquely positioned to be able to provide that to them. So, the takeaway here is that it is a vast geography that we are supporting with 13 buyers and one problem set, but the priorities seem to be aligned. This is Canada in brief. This is where we sit. Andréas Elgaard talked about the long-term care penetration that we have in Canada and our market leadership. So 65% of our revenue today comes from the Long-Term Care sector and 27% in Acute Care. So there is a presence there for sure. You will hear more about this. We are looking to grow that more significantly, but it is Home Care that represents our presence in the community, where we largely use a network of dealers to help penetrate. And then there is a 2% contribution from other, which is the distribution of a small portfolio of products. But more importantly, if I bring your attention to the middle. Here we see the breakdown by product category. So if Arjo Canada was a house, what you can see here is that the pillars of that house are patient handling, hygiene, rental, and service. That is what keeps the house up. We have market leadership positions in patient handling, market leadership positions in hygiene, and market leadership positions in rental solutions, which are almost exclusively distributed through Acute Care. And then we have our strong service offering to support all of those products. We also sell medical beds and services across the country, predominantly in Acute Care, VTE prevention, and reprocessing. When we look at the footprint of Canada, we see 240 employees across the country, with a central warehouse just outside of Toronto in Mississauga, Ontario. We have, like the US, almost exclusively direct sales, service, and clinical offerings, which again to mirror the US, creates a more intimate experience for the customer. We have 11 service centers that we utilize to execute our rental operations throughout the country, and a production facility in Magog, QC, which is a global manufacturing facility; very vast, big geography, 8,000 km almost from coast to coast and pockets of population not dissimilar. I had a conversation earlier about Sweden, which helped identify opportunities for us; when we talk about being direct with our customers, we face large territories to cover in areas where the population is less dense. So we'll take a look here and transition to how we've been doing recently. So I say five plus years of growth, but really this goes back to Arjo becoming a standalone company in 2018. And we see consistent results. So we have a plus 9% revenue CAGR from 2021 to 2025. 22 consecutive quarters of growth going back to Q4 of 2020 and consistent year-over-year development and profit improvement. That is what we have accomplished recently. The how is even more exciting. So the introduction of a dedicated, consistent sales management process accompanied by a really targeted commercial excellence program where we've intentionally pursued defining who are we talking to and what are we talking about with our customers? When I take a look at the corporate groups that we've been able to enhance our relationships with, we've, like the US, really focused on progressing towards solution selling from products. So being less of a vendor and more of a problem solver, which has had a big impact on our relationships with our corporate groups and has allowed us to expand that business by bringing on competitive corporate groups. And we've been able to do that because the rental business is so stable for us in Canada, and the rental business has allowed us to divert resources and opportunities elsewhere. And so, we are focusing on what we have been able to accomplish with that rental business since the acquisition of it in 2012. And then lastly, and Andréas also spoke about this a little bit. It has never been more important to us that we have a global manufacturing facility in Canada, and we utilize that. We utilize that to create efficiencies in our supply chain by direct shipping from that global manufacturing site as well. In recent months and years, it has been really impactful for us to claim Made in Canada. And we've been able to utilize that to penetrate our customer base, and we've been able to really navigate the geopolitical impact of the supply chain for patient handling specifically. So that growth that we've experienced recently has come from a very disciplined execution in the segments that we know best. And the question is, where do we go from here and how do we press that advantage? Andréas Elgaard introduced the strategy to you today. One of those strategic imperatives was where we have the right to play. And that's exactly what we intend to do in Canada. A deeper penetration into Long-Term Care, a stronger penetration into Acute Care, and the exploration of Home Care a little bit more intimately. I will talk about each of those very briefly here, one at a time, starting with strengthening and scaling in Acute Care. So we have an opportunity to leverage the footprint beyond our rental business; there are approximately 94,000 beds that are in target for us in Canada, and the opportunity there is to expand to the full Arjo portfolio. Despite the synergies between the two countries, Arjo Canada and Arjo US work very closely together, and there are a lot of key learnings that we are looking to build on from the US penetration into Acute Care. Our commercial strategy here has been to introduce a direct Acute Care sales team in the most populous areas of the country. We believe that that dedicated effort will allow us to create stronger relationships and penetrate further with the full portfolio. And at the same time, the need to defend and expand on our rental solutions. Which is one of the core areas of our business. And we supplement that by growing via our solutions in patient handling and wellness. In Long-Term Care, we are viewed as, and are, market leaders. And yet it still remains an attractive area for us to expand. There are approximately 200,000 long-term care beds in Canada, and that number is growing because there have been recent announcements of funding for new long-term care beds. Knowing the impact of the aging population, of course. And yet we feel like we are under-penetrated with one of the key product portfolios that we have, which is therapeutic surfaces and, to a lesser extent, medical beds. But the commercial strategy here is to utilize the brand reputation that we have in acute care of having solutions that treat and prevent pressure injuries, and bring those solutions into long-term care, establishing partnerships with long-term care homes that are struggling a bit with resources to have outcomes-based programs that target pressure injury prevention and minimize transfers between long-term care and acute care. And lastly, aggressively pursue winning these new build projects, which we have been securing over the past several years. But as they are ramping up, we want to make sure that we are well-positioned to work with architects, builders, and some of our big contractors and customers to ensure that we are winning these new build projects. Lastly, we look at selectively exploring our enhanced presence in home care. We know that provincial governments are actively investing in keeping people at home for as long as they can. We know that people want to stay at home as long as they can. We also know that there are not enough institutional beds, so this creates an opportunity for us to establish a larger presence in the home care sector. So we are also investing in a more dedicated team here with a stronger strategy and setup for commercial execution. We want to utilize again therapeutic surfaces to promote prevention in home care. And we look at stakeholders that we don't have a strong relationship with today that we'd like to build a stronger relationship with tomorrow, such as the occupational therapists and physical therapists in the community. And lastly, we are introducing more flexible models to effectively navigate through the home care sector in Canada. So in summary, Canada remains an attractive market for continued success. What we have to do going forward is build on our commercial momentum that we have built up over the past few years, the significant momentum we have built up, to pursue targeted opportunities across all sectors where we have the right to play. And lastly, I'll leave you with this. We are positioned to deliver consistent, sustainable results. And that's what we strive to do. And with that, I am going to welcome Andréas back to the stage.

Andréas Elgaard
64:06 - 74:19

Thanks, Jim. Great. So, big thanks to Jessica and Jim. I think it gives a deeper perspective, especially considering that I am up here. We need someone who is actually a professional as well. Jokes aside. I hope so far that you have seen that we are ambitious about the future, but we are also honest about where we have perhaps not performed as well in the past and where we have room to improve. It is clear that every person I meet at Arjo and every topic we discuss demonstrates that there is potential. There is a potential to grow and develop. There is a potential to do better. And that is really what we focused on, and when we combine that with what to expect for the coming years, that is what I will go into now, so we can be confident in what we say. So we've been looking across all parts of Arjo. And what we then commit to today is this 350 MSEK EBIT improvement compared to 2025. We need to have a base when we make these promises. We do not know the future, but we have a clear line of sight regarding the things that will deliver towards this. And also we have potential that goes beyond. We have mainly focused on efficiency, coming out of clarity in roles and responsibilities, enabling the organization to work better together to empower our regions and markets to do what they do best; that is to lead and take care of our customers and ensure that patients receive the healthcare they need. By doing so, we are also harmonizing the best practices we have, including the most efficient way of delivering our rental solutions and the most effective ways of driving a service organization. So there's a lot of that, but it really starts with empowerment and collaboration, and we need to be humble that as individual leaders or individual teams, we don't know everything. We are not the best. Even if we are great, there is always somebody else that has something we can learn from. And that is really a big part of this. The operating model will come with some cost restructuring because we have grown over the past years, as our staff has grown more than the company has. So there is some efficiency there. But a lot of that comes from clarity in roles and responsibilities. What will happen in individual markets, what will happen on a regional level, and what does that mean for our group functions. Then we have seen significant opportunity in procurement. I have led these types of initiatives in different organizations in the past. I also have many years in an organization that was super focused on procurement efficiency. I can see in Arjo that we have a lot of potential. And this is something that we spent large parts of the first half of the year validating, and we have started the execution of that. So we are off to a good start. It is all about leveraging and professionalizing our procurement and also challenging our current ways of working. So there is really significant potential there. And we have spent the day today talking about commercial opportunities. But we have not built in any growth. So this 350 MSEK figure is not fueled by growth over those years. So it's really about things we can do with our own hands, stuff we have control over that will deliver the total sum of EBIT improvement then, and we talk about mid-2029. But the vast majority of this will happen earlier than mid-2029. But it is also important because this is, in a way, going back to basics by focusing on the core business and our core strengths. Spreading the best practices and ensuring we are more consistent in our execution. So that's all good. But what about the future? What about new markets, new customer segments, and new product segments? What about M&A? And today we are not focusing on that. We focus on what we can control, and that has significant value. But of course, we have looked into what this will mean when we also start to drive growth? What will product portfolio optimization mean in terms of efficiency and across the value chain? This will impact our capital efficiency significantly. There is another initiative that we will look deeper into in the coming period. Supply chain optimization. I think there are some things to do. Not as big a potential perhaps as we have in the other areas. And then, of course, we need to drive our growth. We need to build capability or enhance our competence. And one way to do that is also to leverage M&A in a more clear and a more strategic way than what we have done in the past. So that will also be part of the portfolio. But it's important for me to communicate today that what we talk about comes from these three, and that there is more value creation to be delivered beyond this. I have put together an indicative slide on when to expect this to happen. So the vast majority will happen within the coming two years. But we say that mid-2029 is when the full effect is in place. This also comes with a one-time investment in restructuring in order to free this up. And I would say that we have been conservative here when we make this promise, because we know that we have to deliver as Arjo has promised things in the past and we have not delivered. This time, we are going to deliver. So we have been a little bit conservative here. We have not been as conservative here, because we also do not want to set a target and then exceed it. So we are trying to be prudent in the promises that we make. And you can see that this ramps up progressively over the period, but it's not something that you need to wait a long time for. It is something that we expect to achieve in the near term. And I think this is super important. As I said in the beginning, right now and today, we are focusing on how we will Make the Move. Together. And that is really about unlocking the potential of our core business, building on the strengths that we have, controlling and becoming more efficient in how we spend our money, where we invest, and how we collaborate and work across the value chain. Clarifying a lot of things, making sure that we become more scalable and more efficient before we take the next step and put more on our plate, or maybe then use M&A as a tool. I do not want to say that M&A is off the table. And that is something that will only happen in the future. No, that is something that you need to work with long-term. Sometimes these timelines happen sooner than you expect. So it is something that is part of our parallel work. But we need to build a stronger core, a more efficient core, because the way that we grow today, when we grow, our costs follow. And that is not an efficient way of growing. We need to be able to grow in a way where profitability grows more than the top line. So this is really what to expect from us in the coming years. And in the short period that we have ahead of us, of course, we have an interim report coming up soon. So we still have some work to do. Yes, we still have a few days to finalize our Q3 results. And then we'll present that to you in October. We have a year-end report coming at the end of January, and then we will present new financial targets regarding what to expect from Arjo in that aspect. And that will be presented during Q1. And by that, I will just highlight again the opening slide I had, showing the commitment we are making. It is all about unlocking the potential of being Arjo. And it is a plan that we know we can deliver on. And I can say that because it is not my plan. It is our plan. It is these people who have made that plan. So it is all the professionals like Jessica Shatzer and Jim Findlater that you have met today that have put this plan together. So it's really the result of a co-creation. I told maybe a bad joke, but I told the teams when I was new that we were going to do this and we were going to co-create it. I told them that they were going to develop Stockholm Syndrome. That is how you become part of a journey, and you will realize through that process that you are actually being kidnapped, and you will start to sympathize with the kidnapper, because that is really what happens when you invite people to co-create, to participate, and to contribute. It is no longer your baby; it becomes our baby. And then the trick and the trap is that guess who is going to execute? It is the same team that has developed the plan. It is now their plan. Now they also get the privilege to execute. And that is something that has been really well received. It is what these leaders want. They are. They are really good at execution in their everyday life. But now they have a shared plan that has been understood, and as you know, when you bring a group of people together, they do not always think the same way. So they have really challenged each other, but they've also been partnering, then selecting where do we put our money? Where do we put our time? Where do we put our focus, and how can we deliver that to our purpose in the best possible way? So this is why I am confident that this is a plan that we can deliver. And by that, I say thank you from my side, and we open up the floor for Q&A. And I welcome Maria, Jessica, and Jim to the stage to join me. And let's see if we get some good, tricky questions, or how we move forward.

Maria Nilsson
74:21 - 74:35

Okay, so if you want to ask a question in the room, raise your hand and wait for a microphone. And if you want to ask a question online, tap into the chat box below the video player; who wants to start over here?

Kristofer Liljeberg
74:35 - 74:51

Thank you. Kristofer Liljeberg from Carnegie. I have two questions. Just to make sure, the base you assumed for the 350 MSEK improvement is that? Adjusted EBIT for 2025, I assume, or.

Andréas Elgaard
74:51 - 74:59

You can do that. This is the improvement. So you can take that as you wish. This will be a net improvement.

Kristofer Liljeberg
74:59 - 75:08

And it seems you see this as a saving more than actual EBIT improvement because you do not include any sales growth here.

Andréas Elgaard
75:08 - 75:22

We do not include sales growth in this number, but it is an element of efficiency in how we work together. It is procurement, but it is also on the commercial excellence side. So, it is all of these things.

Kristofer Liljeberg
75:22 - 75:32

Okay. So the actual EBIT improvement, if you continue to grow the business by 3% to 5%, the actual EBIT improvement will be more than 350 MSEK in this period.

Andréas Elgaard
75:32 - 75:36

If the assumption is that we will be more efficient as we grow. Yes.

Kristofer Liljeberg
75:36 - 75:37

Okay. Thank you.

Sten Gustafsson
75:42 - 76:10

Yes. Sten Gustafsson from ABG Sundal Collier. I have a question for Jessica. When you talk about the opportunities in the US in the Long-Term Care segment, I guess that opportunity has been there for quite some time. So I was wondering if there are any structural reasons why you haven't focused on that before and what the competition looks like for you.

Jessica Shatzer
76:11 - 77:04

That is a great question. Starting in 2022, many of you know, we separated North America into US and Canada and post-Covid, we had been struggling from a revenue and financial standpoint and we made a decision at that time. We had to work to turn around the Acute Care and the government business that we had, and we've successfully done that. And that is why today we feel like we can really take on this element of the strategy from a competitive standpoint. The market is highly fragmented in Long-Term Care, and that's why I think from our position, we're able to capitalize on some of that consolidation of the chains. So smaller regional chains are being acquired by larger chains, and they want consistency across their facilities. So Arjo is positioned in a really nice way to do that with the scope that we have.

Sten Gustafsson
77:05 - 77:09

But you do have the products in place today.

Jessica Shatzer
77:10 - 77:18

Mainly, we have a couple of product launches that are due, one of them in Q1 and another later next year that will help significantly.

Sten Gustafsson
77:18 - 77:18

All right.

Andréas Elgaard
77:18 - 77:19

Thank you.

Mattias Vadsten
77:25 - 77:45

Mattias Vadsten from SEB. Thanks for taking my questions. The first question is if you could talk a little bit more about the initiatives taken to be able to charge better for the value add you provide your customers. And if you could also talk a bit about where this is working today for Arjo and where we sort of need material improvement.

Andréas Elgaard
77:46 - 78:52

Yes. We did not share individual countries, but we have several good examples where we have great diligence, and we are being meticulous in our terms and conditions and our commercial execution. And I don't want to point out individual countries that are not doing it as well. But we see that this is clearly within our own reach. And I would say that in many markets, we are a bit unaware. To understand why we will succeed in doing something that we have been able to do in the past, it is because we have not fostered this. I would say cross-border collaboration. We have not had the forums. We have not had the mechanisms. Arjo has largely been managed country by country. We have not had the mechanisms for the countries to interact with each other. So that's also background on this. So when Canada and the US were separated a couple of years ago, there were very few networking opportunities or best practice sharing opportunities. So those are some of the capabilities that we're putting in place.

Mattias Vadsten
78:54 - 79:03

Thank you. And in terms of price pressure you see today, in what segments is this more accentuated?

Andréas Elgaard
79:04 - 79:49

I mean, maybe I shouldn't look at Jessica, but of course, you know that our DVT or VTE or we sometimes call it IPC. We like our abbreviations. I mean, we know that in the US, that is a huge business. But we have seen new, very tough competition. And so the average price level has dropped significantly. That has been followed up in every quarter. I do not see in my crystal ball that that is going to return. That is the new reality of competition. And we need to face that and adjust our business models, because I think that we've had business models where we knew we would catch up if we just got the customer. But now we need to make sure that we're profitable from the get-go.

Mattias Vadsten
79:50 - 80:07

Thank you. And one last question, if I may, in terms of the new operating model, you talk about commercial execution and so forth. So I would expect to hear a bit more on growth perhaps. But would you say this is what we can look forward to as of the Q4 report?

Andréas Elgaard
80:07 - 81:02

I would say that, as you know, we don't give guidance. But today we have given guidance. So this is something that we will follow in every quarterly report, and we will then follow how our execution materializes in the P&L so that it can be separated. And until we have reached our promises, we can go into a more business-as-usual approach. But I think that you can expect to see effects of this coming in during 2027 and 2028. And we will be able to talk more about that. I would say that when we have new financial targets, of course, that will be a wider set of focus, and it will not just be about what we have presented from the strategy. We know that we have an underlying business. I've just said that this is a subset of the things that we're working on, but they are so material and they are so concrete that we want to share them today.

Mattias Vadsten
81:02 - 81:03

Thank you very much.

Maria Nilsson
81:06 - 81:08

Next question.

Ludwig Germunder
81:10 - 81:26

Thank you. Ludwig Germunder from Handelsbanken. I want to start with a follow-up on Mathias. A question about the price pressure that you have seen. You said, Andréas, that you do not expect it to return. But how should we think about that going forward; will it be stable in your view, or do you think there will be more price pressure?

Andréas Elgaard
81:26 - 81:39

I mean, if we talk about the VTE prevention category specifically, I think that we are probably flattening out in terms of price pressure. It has been a steep journey downwards. And I don't know, Andréas, if you want to add something.

Jessica Shatzer
81:39 - 81:55

Yes, I would say that is accurate. I feel like we're very close to the bottom at this point. And so now we are really looking to capture additional customers and keep the existing customers that we have. And then whenever we can, we will try to increase prices in other categories.

Andréas Elgaard
81:56 - 83:12

And to build on that, it also means that if this is the reality of the market, the way that we deliver our solutions has to also improve: where we manufacture, how we manufacture, how we drive supply chain operations, and how we package the goods. It is easy and efficient, and it also concerns how we build stickiness in our customer relationships, because this is a segment with a high level of consumables. And it is really once you are in there with a customer, it is a really recurring revenue type of business. So we do want to keep being there. Generally, regarding price pressure across all categories, I don't see that changing anytime soon; the pressure on Arjo and the whole market, given the constraints health care systems are under, means I don't think we will have easy sailing in the future. So we need to work on our own efficiency, we need to work on our own relevance. That also links back to what I think both Jessica and Jim were talking about. We need to show how we deliver our value and be more of a solution provider than just a product provider. We need to show how this solution delivers reduced costs and relieves pressure from staff and so on.

Jessica Shatzer
83:13 - 83:29

If I could add to that just briefly, it also connects to the sustainability and the reprocessing that we mentioned today. That is a big element where, if you combine the offering that we have with reprocessing, you can provide additional value. There are cost savings on our side. So it's really a win-win for the customer and Arjo.

Ludwig Germunder
83:31 - 83:50

Great. Thank you. And just a second question to understand where you stand today. So I understand this. It has been extensive work with this strategy that you have presented today. But in terms of financial targets that you aim to present in Q1, what are you missing today that is holding you back from presenting targets today? For example.

Andréas Elgaard
83:50 - 85:09

I would say that it is part of the line of questioning that you have had. I think what we will come back with is how we will manage capital in a better way. I think that is important. I think we have all seen that cash flow generation has not been where it should be. So there will be additional focus on capital efficiency and what that means in terms of financial targets. I think that what we have seen when we have been working on the strategy and the energy we get out, and I would say also the inspiration. When you bring people together to explore our own company again and our own opportunity, that has been really revealing. So, of course, if we see potentials that are there that are untapped, that needs to be built into our growth ambition. So that's something we need to come back to. Then I think also, maybe it is our own fault, but I think that we have talked maybe a little bit too much about gross profit and growth and not enough about the bottom line. So I think that we will have more focus on profitability, making sure that whatever we do, whether the margin is high or low, that by the end of the day, we measure if we are actually delivering value to our shareholders. And I think that needs to be stronger. That is an element we must emphasize when we present our financial targets.

Ludwig Germunder
85:11 - 85:12

Thank you.

Maria Nilsson
85:13 - 85:21

So I will take a quick question from online as well. Andréas, would you like to elaborate a little bit on where we intend to invest for the future?

Andréas Elgaard
85:23 - 87:46

Yeah. In terms of, I mean, it is a broad question. So I think if I start on the people side, we intend to invest in developing the leadership of our leaders. We have great people, but they are not used to collaborating across borders. They are fantastic within their own domain, but they have not been given the opportunity to collaborate and manage. I would say multiple priorities and multiple needs, and to be comfortable in that. Also, to help them better navigate when you are operating in the unknown. Because we know that the world is not as stable and predictable as it used to be. And as a leader who has many years in an industry, when the fundamentals around you are changing, you lose the leverage that you have with your organization. We need to help them realize that leading in the unknown is very different from leading in the known. You need to engage your people. You need to empower your teams much more, and you need to bring more people into that process. So we will invest in our people, for sure; that is something we also need to invest in our capabilities regarding how we drive efficiency. Then when it comes to looking forward into the market, I think that we have said already today that if we want to penetrate in Long-Term Care, that doesn't happen by itself. We need to have dedicated investments. So we need to invest in people and we need to invest in our infrastructure. I would say sometimes facilities; I think we cover, if we talk about the US and Canada, we cover the markets pretty well. So we have a lot to leverage from, but that is where the investments will be in market penetration. And then if we do more targeted, or if we do something that is more M&A related, of course, that will also be part of that. When we look into the portfolio, I would say that we need to mature how we work with our partners. Arjo needs to lead. We can never abdicate our leadership, but we need to also leverage the competence that comes from some of our partners. And we have not always done that and not always realized that they also have engineers. They also have creativity. So we need to empower also our partners to be more closely connected to our product development processes and to how we then deliver that offer to our markets. So the investments will happen broadly across. And if we engage in M&A or similar activities, that will be communicated when it occurs.

Kristofer Liljeberg
87:51 - 87:53

Hello, Erik Cassel from Danske Bank.

Ludvig Lundgren
87:54 - 88:07

First, regarding the timing of the savings. When you say mid-2029, is that some sort of annualized run rate by that point, or is it realized on a rolling 12-month basis? By that point.

Andréas Elgaard
88:07 - 88:12

It will be realized at that point, and the vast majority will happen before that.

Ludvig Lundgren
88:13 - 88:24

And then I was wondering, on the 371 MSEK investment, what is the proportion of that affecting cash flow? Is there any sort of non-cash component to it?

Andréas Elgaard
88:25 - 88:47

That will affect cash flows and will be connected to capability investments. I would say in operations, it will also be investments in, as I said, market penetration. And there will be investments in organizational efficiency.

Ludvig Lundgren
88:47 - 89:16

Okay. Thank you. And then, can you share a bit more regarding the proportion that comes from the different buckets that you showed? You had some indicative circles in there, but is it possible to say how much is more certain regarding headcount reductions and maybe a bit, say, unsure regarding procurement factors that you may be uncertain on for timing and magnitude. For example, how much is certain of the total savings?

Andréas Elgaard
89:16 - 90:03

Yeah. So, of course, we work internally with targets that are even higher because we need to have ambitions that enable us to deliver on the targets we share today, as we all know there are risks in execution and not everything will be fully realized. But we are confident that we have seen enough ambition and enough potential that we can deliver on this promise today. So we have not broken down exactly how much will come. The illustrations there are there for a purpose. They are indicative, but you can also see what they indicate. So I think that is the answer that we give today. I am quite sure that when we come back in the coming quarters, we will be able to share more about that.

Ludvig Lundgren
90:05 - 90:15

Good. Thank you. And then I was wondering if the new model has any implications for cash flow generation. Do you expect to have some sort of linear net working capital effects from this?

Andréas Elgaard
90:16 - 90:44

We believe that. The new operating model will definitely help us reach better cash flow generation. I would say that a lot of what I talked about regarding portfolio pruning and efficiency will help us to drive cash flow generation, as we can improve our cash efficiency by addressing the capital we are currently tying up in various areas.

Ludvig Lundgren
90:44 - 91:02

Okay. And last question, as you talked about retiring products and slimming SKUs, do you expect that to be a notable headwind on growth in the coming years? Are you willing to give up, say, the recent year's growth rate in favor of lifting margins?

Andréas Elgaard
91:03 - 91:56

I would say that shareholder value will be our ultimate purpose. We do know that we still take care of products that were launched more than 20 years ago, sometimes 30 years ago, and we still keep them alive even though they are not generating significant sales. So, of course, when you do portfolio pruning, it comes with trade-offs. And what usually happens is that in the beginning it feels difficult, but in the end, you actually unleash sales to have more predictability in the availability of products. It usually is a good growth driver. It intuitively seems like the opposite, but usually it actually helps you to become more efficient. And that helps sales to be more efficient. But of course, this is not something that we will do from an inventory point of view; it will be something that we do from a value chain point of view. So how do we create the best value, and how do we then create that across the organization?

Maria Nilsson
91:59 - 92:02

Do we have any further questions? Yes. Over here.

Unknown 3
92:07 - 92:29

So, we talked about pricing. But another reason for lower profitability in the last year has been geographic mix, where the US and Canada have grown slower than other regions. And now you talked about the new strategy in North America. So going forward, do you anticipate that negative trend to reverse? And we will see higher growth in North America compared to the rest of the world.

Andréas Elgaard
92:30 - 94:06

I think that if you look at gross profit, it is one story. If you look at the bottom line, it is another story. I think that is also part of what we need to focus on; at the end of the day, when we have been busy executing everything we are doing and realizing the growth we have created, it is what is left on the bottom line that we need to be much more focused on. And I think that Arjo has had too much focus on top line and gross profit and not enough focus on the bottom line. I am not saying that we will stop thinking about that. I am just saying that we need to make sure that keeping ourselves busy results in tangible outcomes. And that is part of becoming more performance-driven in our culture. So I hope that answers your question. For instance, earlier this year, we communicated that we won a huge deal in South Africa, a significant medical beds deal. And of course, regarding gross profit. You can imagine this for yourself. We are selling medical beds to healthcare institutions across South Africa. The gross profit is not the best. So it brings down the average. But the bottom line is good. And the capital efficiency was excellent. We got paid before we had to pay our own invoices. So sometimes there is more behind the gross profit. I believe that we have been too focused on a couple of indicators that are perhaps true for parts of our categories, but for other categories, they tell a different story. And I think that's why, at the end of the day, the bottom line is where we need to have our focus. And that is also why I sent a message today talking about EBIT improvement and not on higher up in the P&L.

Unknown 3
94:08 - 94:46

One more question, if I may, on cash flow. You currently spend around 600 MSEK on capital expenditures each year, which is approximately 5% of sales. And you mentioned that expanding into Acute Care will result in some investments. So what is the normalized level of capital expenditures to maintain the current base and deliver on the new growth targets? I mean, currently you only deliver around 20% to 30% of Adjusted EBITDA to free cash flow. So what is a level you would be happy with?

Andréas Elgaard
94:47 - 96:22

We are not setting financial targets today. I apologize for the straightforward answer, but as I mentioned earlier, we need to focus on our capital efficiency because we know we are not being efficient today, and not enough is being converted into real cash flow by the end of the day. And we can see that our debt has been flat for a period. And we came from a period where we gradually worked our debt down, and then it has stopped. So portfolio focus has many aspects to it. It is not just about developing an offer that the customers like. It's also developing an offer that is more efficient across the value chain. It's more efficient in assembly. We need to leverage our OEM partners as well. So we make sure that we take the right make or buy decisions. And I think that historically we have maybe taken these decisions in silos, and we have not done that from a value chain optimization point of view. I am used to that way of working. And I think many people across Arjo have similar experiences, but as an organization, we have not had that decision-making or that operating model governance. So, I expect us to be able to improve the capital side as well. But today we cannot talk about that. We have been busy reaching the point where we are today, and we think it is significant enough to take our time and your time to share that. And then we really hope to come back in Q1 with financial targets where we can talk more about that.

Kristofer Liljeberg
96:27 - 96:27

Hi.

Ludvig Lundgren
96:27 - 96:29

Ludvig Lundgren from Arctic.

Mattias Vadsten
96:29 - 96:31

So starting.

Ludvig Lundgren
96:31 - 96:46

With a bit of a follow-up on the 370 MSEK one-time investments, you highlighted that these will be incurred by 2027, but can you elaborate a bit on the timing of these costs? And will we see a material effect already in 2026?

Andréas Elgaard
96:46 - 97:38

They will be largely incurred in 2027, but also parts of it will go into 2028 because we will make changes across the company that need longer lead times before we can execute them. You need to build up a capability before you can execute on some parts of it. However, we will not elaborate on exactly what that consists of. Of course, we know that based on our plan, the figure that we have put out is conservative, which means that it might be less, but we also put out a conservative figure in. Regarding the 350 MSEK target, it might be more. So we are trying to match those two. So if the 350 MSEK target becomes higher. I do not want the 370 million SEK to grow. I want to be able to deliver more value.

Ludvig Lundgren
97:38 - 98:03

Okay. Very clear and, um. Yeah. And then I had one for Jim. Because I believe the Long-Term Care in Canada is operated by both public and private facilities. So I just wonder if you can give some flavor on what type of facilities Arjo is struggling with currently. And can you identify any trends in the market for both types of facilities?

Jim Findlater
98:03 - 98:55

No, that's a very good question. Yes, currently, we are in just under 75% of Long-Term Care facilities across the country in some capacity over the past ten years. And that number really does split between the public and the private. I would say that we have equal partnerships with both. I think when you look at the private sector, that's where you get more into the corporate accounts or group purchasing organizations, which may have a greater ability to be impacted from a top-down level. But still, the publicly funded system views us as market leaders, they trust us, and we work with them effectively. I'd say the big difference between the two is that you have a more top-down approach with the privately funded corporate groups. If that answers the question.

Ludvig Lundgren
98:55 - 99:16

Yeah, thanks. And then if I just squeeze one more in, just a bit of a follow-up to my first one; because it sounds like some of the costs will be in the P&L and some will perhaps be capitalized, should we expect a bit of an initial margin decline from these investments, which will then drive margins in the longer term? Is that the correct way to interpret these initial investments?

Andréas Elgaard
99:17 - 99:40

I think that all of you understand that we talk a little bit in riddles about some of these things because it is not until we have executed some of the initiatives that we will have the true cost. So, it will be mainly a P&L effect in that restructuring. That is the message that I can give today.

Ludvig Lundgren
99:42 - 99:43

Thanks. Very clear.

Maria Nilsson
99:46 - 100:10

Are there any further questions in the room? No. So then I think we are ready to wrap this up. Before I hand over to you for some final comments, I just want to say that if you have any further questions or want to connect, feel free to reach out to any of us. And then over to you, Andréas.

Andréas Elgaard
100:10 - 100:24

Yeah. I do not have much to say. No, I just want to say thank you for listening to us. And also thank you to Maria, Jessica and Jim, because I think you were dynamite today. So really good. Thank you guys. Thank you, guys. Thanks. And thanks to all of you.

Unknown 4
100:25 - 100:25

Thank you.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…